Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kushner

Showing results (231-240 of 245) with videos related to

Pageof 25
Sort By:
Journal of Neuro-Oncology|November 6, 2009
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaKim Kramer, Brian H Kushner, Shakeel Modak, et al.
Cancer Research|June 17, 2021
An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast CancerGhada M Sharif, Moray J Campbell, Apsra Nasir, et al.
Journal of Pediatric Surgery|October 6, 2010
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infectionsMark L Kayton, Edward G Garmey, Nicole M Ishill, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 8, 2000
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitorsM D Megonigal, N K Cheung, E F Rappaport, et al.
Nature Communications|February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trialJaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
Oncoimmunology|September 18, 2018
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I studyShakeel Modak, Jean-Benoit Le Luduec, Irene Y Cheung, et al.
Journal of the National Cancer Institute|December 16, 2014
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancerAustin N Kirschner, Jie Wang, Riet van der Meer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapyB H Kushner, M P LaQuaglia, N Wollner, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Medical and Pediatric Oncology|July 24, 2001
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of ageN K Cheung, B H Kushner, M LaQuaglia, et al.
Pageof 25

Showing results (231-240 of 245) with videos related to

Sort By:
Pageof 25
Journal of Neuro-Oncology|November 6, 2009
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaKim Kramer, Brian H Kushner, Shakeel Modak, et al.
Cancer Research|June 17, 2021
An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast CancerGhada M Sharif, Moray J Campbell, Apsra Nasir, et al.
Journal of Pediatric Surgery|October 6, 2010
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infectionsMark L Kayton, Edward G Garmey, Nicole M Ishill, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 8, 2000
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitorsM D Megonigal, N K Cheung, E F Rappaport, et al.
Nature Communications|February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trialJaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
Oncoimmunology|September 18, 2018
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I studyShakeel Modak, Jean-Benoit Le Luduec, Irene Y Cheung, et al.
Journal of the National Cancer Institute|December 16, 2014
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancerAustin N Kirschner, Jie Wang, Riet van der Meer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapyB H Kushner, M P LaQuaglia, N Wollner, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Medical and Pediatric Oncology|July 24, 2001
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of ageN K Cheung, B H Kushner, M LaQuaglia, et al.
Pageof 25